Royalty Deal Drove After-Hour Rally In Omeros (OMER) Stock
Royalty Deal Drove After-Hour Rally In Omeros (OMER) Stock
Omeros Corporation (NASDAQ: OMER) shares continued their ascent on the US stock market, persisting even after the close of business yesterday. Omeros' stock witnessed an impressive surge of 8.82%, reaching $3.7 during the extended trading session. This increase followed a 4.94% rise in the regular session, concluding at $3.40. The surge in OMER stock was triggered by the execution of a noteworthy royalty purchase agreement by the company.
Omeros公司（納斯達克股票代碼：OMER）的股價繼續在美國股市上漲，即使在昨天營業結束後仍持續上漲。Omeros的股票大幅上漲8.82％，在延長的交易時段內達到3.7美元。這一增長是在常會上漲4.94％之後出現的，收於3.40美元。OMER股票的飆升是由該公司執行一項值得注意的特許權使用費購買協議引發的。
Today, Omeros (OMER) revealed the transfer of an expanded stake in particular royalty proceeds tied to the net revenue from OMIDRIA in the United States to DRI Healthcare Acquisitions LP ("DRI"), a wholly-owned subsidiary of DRI Healthcare Trust. Originally designed and introduced by Omeros, OMIDRIA is a revolutionary ophthalmic instrument intended for use in cataract and lens replacement procedures.
今天，Omeros（OMER）透露，擴大的股份，特別是與美國OMIDRIA淨收入相關的特許權使用費收益，已轉讓給DRI Healthcare Acquisitions LP（“DRI”），該公司是DRI Healthcare Trust的全資子公司。OMIDRIA 最初由 Omeros 設計和推出，是一款革命性的眼科儀器，用於白內障和晶狀體置換手術。
Rayner Surgical Inc. received OMIDRIA and its associated business assets from Omeros in December 2021. As per the conditions mentioned in the asset purchase agreement, Omeros is qualified to receive royalties that are determined by OMIDRIA's net sales. Omeros and DRI entered into a royalty acquisition agreement on September 30, 2022, which brought Omeros a monetary benefit of $125 million.
Rayner Surgical Inc. 於 2021 年 12 月從 Omeros 獲得了 OMIDRIA 及其相關業務資產。根據資產購買協議中提到的條件，Omeros有資格獲得由OMIDRIA的淨銷售額確定的特許權使用費。Omeros和DRI於2022年9月30日簽訂了特許權使用費收購協議，這爲Omeros帶來了1.25億美元的金錢收益。
This was given in return for a share, restricted by yearly limits, of Omeros' royalties on global net sales of OMIDRIA payable by Rayner from September 1, 2022, to December 31, 2030. Presently, Omeros and DRI have expanded their royalty purchase agreement, leading to Omeros receiving an upfront payment of $115 million from DRI.
這是爲了換取雷納在2022年9月1日至2030年12月31日期間支付的歐美羅斯對OMIDRIA全球淨銷售額的部分特許權使用費，但受年度限額的限制。目前，Omeros和DRI已經擴大了特許權使用費購買協議，使Omeros從DRI獲得了1.15億美元的預付款。
This entitles DRI to the remaining royalties on U.S. net sales of OMIDRIA, payable between January 1, 2024, and December 31, 2031. Excluding the purchased royalties, DRI holds no claim to Omeros' assets. As part of the extended agreement, the outstanding balance of $174 million in annual caps payable by Omeros to DRI has been extinguished.
這使DRI有權獲得美國OMIDRIA淨銷售額的剩餘特許權使用費，該特許權使用費將在2024年1月1日至2031年12月31日之間支付。不包括購買的特許權使用費，DRI對Omeros的資產沒有任何索賠。作爲延期協議的一部分，Omeros每年向DRI支付的1.74億美元上限的未清餘額已經消除。
Furthermore, Omeros stands to receive two milestone payments from DRI, each amounting to a maximum of $27.5 million, scheduled for disbursement in January 2026 and January 2028, contingent on meeting specific OMIDRIA net sales thresholds.
此外，Omeros將從DRI獲得兩筆里程碑式的付款，每筆最高金額爲2750萬美元，計劃於2026年1月和2028年1月支付，前提是滿足特定的OMIDRIA淨銷售門檻。
譯文內容由第三人軟體翻譯。